Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015

Sang-Uk Lee¹,³, Minah Soh¹, Vin Ryu¹, Chul-Eung Kim¹, Subin Park¹, Sungwon Roh², In-Hwan Oh³, Hye-Young Lee¹ and SungKu Choi¹*

Abstract

Background: Schizophrenia is a recurrent, debilitating disease that is rarely curable. Rapid intervention after the first episode of schizophrenia has been shown to positively affect the prognosis. Unfortunately, basic data is scarce on first-episode schizophrenia in Korean patients making it difficult to create a comprehensive list of risk factors for relapse. This study aims to investigate the demographic characteristics and institutional factors of patients with first-episode schizophrenia in order to identify risk factors for relapse.

Methods: Data from the Health Insurance Review & Assessment Service (HIRA) was used for this study to represent the Korean patient population. To identify factors affecting relapse, we explored gender, age, geographic location, medical benefits, type of medical institution, type of medication used, medication adherence, and the severity of symptoms. Data analysis was performed using the Cox proportional hazard model.

Results: The number of patients diagnosed with first-episode schizophrenia in Korea over a 2-year period was 4567 of which 1265 (27.7%) patients experienced a relapse during the observational period. Factors affecting relapse included age, type of medical institution, type of medication used, medication adherence, and type of treatment (inpatient or outpatient) after the initial diagnosis, which varied depending upon the severity of symptoms.

Conclusions: It was found that environmental and institutional factors as well as the type of medical treatment were crucial in determining whether patients with first-episode schizophrenia subsequently relapsed. The results of this study can be utilized as source material for directing therapeutic interventions and improving mental health policies in the future.

Keywords: First-episode schizophrenia, Relapse, Medical institutions

Background

Schizophrenia has a prevalence of approximately 1%, and a considerable proportion of patients are resistant to treatment after they have progressed to the chronic stage of the disease. The quality of life of patients with chronic schizophrenia is diminished due to cognitive dysfunction, paresthesia, disordered thoughts, deterioration of emotional control, and negative symptoms [1, 2]. There is a great deal of evidence that early intervention should be conducted after the first episode of schizophrenia to ameliorate symptoms and improve the overall prognosis. The first 5 years is the most important period following the initial episode of a mental illness and is referred to as 'the critical period'. Psychosocial and biological interventions performed during this period have been shown to positively influence the prognosis of the disease [3, 4]. Pharmacotherapy is considered to be the most important element of schizophrenia treatment, and roughly 80% of patients with first-episode schizophrenia improve within 6 months of starting medication [5, 6]. Gaebel et al. revealed that 91.5% of patients showed symptomatic remission, and 58.6% of patients remained in remission through their 1-year follow-up [7].

Once schizophrenia recurs, the psychiatric symptoms appear repeatedly, and hospitalization is recommended in
many cases. The readmission rate is directly proportional to the rate of relapse, and hospitalization after treatment can thus be considered an index of relapse [8, 9]. One study reported that 41.0% of patients with schizophrenia were readmitted to a hospital within 1 year of discharge [10]. Another study indicated that 42.0% of patients with first-episode schizophrenia were readmitted to a hospital within 2 years [11]. Similarly, a Korean study also showed that 33.3–35.6% of patients with schizophrenia were re-hospitalized within 2 years [12, 13]. Collectively, the results from Lin et al., Sara et al., Kim et al. and Lee et al. studies may point to the possibility of relapse in patients with schizophrenia. Furthermore, relapse worsens a patient’s future response to treatment, lowers their quality of life, leads to social isolation, and raises social costs [14]. Relapse in younger patients with schizophrenia can have an even greater impact on their future lives, separating them from schools, workplaces, friends, and social communities [15]. Treatment with an antipsychotic drug is the most promising strategy for relapse prevention, and the risk of relapse is inversely proportional to medication adherence. Therefore, many studies have explored the correlation between relapse and treatment-related variables such as medication adherence [16–18]. There are, however, no studies examining institutional factors such as the type of medical institution where treatment was provided. Moreover, studies on relapse are limited to a one hospital or outpatients based study in Korea. This study investigated demographic characteristics and institutional factors of patients with first-episode schizophrenia in order to identify risk factors for relapse. Data from the HIRA was used for this study to better represent the Korean patient population.

Methods

Data

This is a retrospective study using health insurance claims data provided by the HIRA from January 2011 to December 2015. In Korea, 98% of the population is covered by the national health insurance, thus the claims data represent the whole population treated for a specific illness [19]. Based upon the health insurance claims data, patients included in this study were diagnosed with code F20 of International Classification of Diseases, 10th Revision (ICD-10). Patients who were not diagnosed with F20-29 in 2011–2013 but were then diagnosed with F20 after 2014 were defined as having first-episode schizophrenia for the purpose of this study [20]. The medications prescribed for each patient were found in the detailed drug statement. The medications were classified as either antipsychotic drugs or other drugs (antiepileptic drug, hypnotics & sedative drug). Antipsychotic drugs were then subdivided into monotherapy or combination therapy (2 or more drugs). Based upon methods used in previous studies, patients were grouped by medication adherence as follows: 0–50%, 50–80%, and more than 80% [21–23]. Medical institutions providing the treatment were classified into three groups according the number of beds: clinics have fewer than 30 beds, hospitals have 30–99 beds, and tertiary hospitals contain more than 99 beds. In the Korean mental health care system, tertiary hospital usually treats the patients with acute schizophrenia. But overall links between parts of the health system are not strong and there is little referral pathway. Therefore, patients usually choose the medical institutions that they think most appropriate [24]. Thus, there is little difference among medical institutions regarding type of patients, diagnosis and etc. To estimate the severity of symptoms, any patient who received outpatient treatment without hospitalization following their initial diagnosis of schizophrenia was considered to be a mild case.

Medication adherence

Antipsychotic drug adherence was measured using a method proposed by Steiner and Prochazka in 1997 [23]. In this method, (A) is defined as the total number of days from initial diagnosis until either hospitalization or observed termination of the first medication, and (B) is defined as the number of days treated with a medication. The ratio of B to A is then referred to as the ‘adherence’. Patients were then divided into one of three groups based on their calculated adherence: 0–50%, 50–80%, or more than 80%.

Selecting subjects

A total of 96,618,772 claims with a diagnostic code of F20-29 from the HIRA from January 2011 to December 2015 were analyzed. Of these, 202,978 patients who were not diagnosed with F20-29 from 2011–2013 but were diagnosed with F20 in 2014–2015 were selected. Using standards established by prior studies, only patients aged 14–30 years old at the time of their initial diagnosis were included [25]. In order to increase the diagnostic accuracy, patients diagnosed with F20 more than twice were included in this study only if they were outpatients. Patients who also carried a diagnosis of mental retardation, epilepsy, stroke, Parkinson’s disease, or any organic brain disorder were excluded. This yielded a final study population of 4567 patients (Fig. 1).

Statistical analysis

The observation period for relapse in the 4567 patients selected with first-episode schizophrenia took place between January 2014 and December 2015. The observation period was scored on a monthly basis. We defined
admission as an event, in the survival analysis. Admission was regarded as a result of relapsed schizophrenia [9]. Patients who relapsed were scored ‘1’ and those who did not relapse were scored ‘0’ for survival analysis. To identify the factors affecting relapse, the following variables were used: gender, age, geographic location, medical benefits, type of medical institution, type of medication used, medication adherence, and type of treatment (inpatient or outpatient) after the initial diagnosis.

The risk factors affecting relapse were analyzed by the Cox proportional hazard model. This technique does not assume any particular distribution, because it is impossible to presume a theoretical distribution of subjects’ survival time. As such, the Cox model is advantageous in that the data’s baseline hazard function provides a stable estimate of coefficients [26]. The hazard ratio (HR) and 95% confidential interval (CI) were measured through this COX proportional hazard model, and statistical significance was defined by a 5% confidential level using the two-sided test. SAS Enterprise Guide software version 6.1 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analysis.

Results

The average age of the 4567 subjects with first-episode schizophrenia was 23.12 years. Of these, 1265 (27.7%) of patients experienced a relapse during the observation period, and significant differences were found between groups according to the type of medical institution, type of medication used, medication adherence, and the severity of symptoms. Patient characteristics including gender, age, geographic location, medical benefits, type of medical institution, type of medication used, medication adherence, and the severity of symptoms are presented in Table 1.

The average follow-up period was 11.8 months with a median of 12 months. The shortest and longest follow-up periods were 1 and 24 months, respectively. During the follow-up period of 4475.1 person-years, a total of 1265 subjects were admitted to hospitals, and the calculated rate of relapse by person-years is shown in Table 2.

Risk factors for relapse in patients with first-episode schizophrenia

To analyze the variables affecting relapse in patients with first-episode schizophrenia, a Cox-regression was performed. After adjusting for the variables of gender, age, geographic location, medical benefits, type of medical institution, type of medication used, medication adherence, and the severity of symptoms, significant differences were found in the hazard ratio (HR) according to age, type of medical institution, type of medication used, medication adherence, and the severity of symptoms. The risk for relapse appeared low (HR of 0.96) in patients with a delayed age of onset. The HR of community hospitals compared with tertiary hospitals was 1.17, which was significantly high. The HR of clinic-level facilities compared with tertiary hospitals declined significantly to 0.75. The HR of other drugs compared with monotherapy with antipsychotic drugs was 2.09, which was significantly high. After dividing patients into three groups based on medication adherence, the HR of the group with 0–50% adherence compared with the group with more than 80% adherence was 1.59, a significantly high result. Using the severity of symptoms, the HR of the patient group who received inpatient treatment compared with the group who only received outpatient treatment after the initial diagnosis was 1.46, another significantly high result (Table 3).

Risk factors for relapse in patients with first-episode schizophrenia by severity

To estimate the severity of symptoms, we explored whether subjects received inpatient or outpatient treatment after the initial diagnosis. Patients were divided into two groups based on the type of treatment, and variables from each group were analyzed after being adjusted. Looking at age, the risk for relapse appeared low in patients with a delayed age of onset, regardless of the severity. In the outpatient treatment group, the HR of 26–30 year-olds compared with 14–19 year-olds was 0.78. In the hospital treatment group, the HR of 20–25 year-olds compared with 14–19 year-olds was 0.76, and the HR of 26–30 year-olds compared with 14–19 year-olds was 0.60. This indicates that the HR of
patients aged 14–20 with first-episode schizophrenia was significantly high. With all other variables, the HR trended according to the severity of symptoms (Fig. 2).

In the patient group who received outpatient treatment in clinic-level facilities after the initial diagnosis, the relapse HR was 0.71 compared with those treated in tertiary hospitals, a significantly low result. The HR of patients treated with other medications but not antipsychotic drugs was significantly high at 2.11. The HR of the

Table 1 Demographical characteristics of patients with first-episode schizophrenia

| Characteristics        | Categories          | No relapse | Relapse | (P value) |
|------------------------|--------------------|-----------|---------|-----------|
|                        |                    | n = 3302  | n = 1265|           |
|                        |                     | 72.30%    | 27.70%  |           |
| Gender                 | Male               | 1654      | 635     | 0.9485    |
|                        | Female             | 1648      | 630     |           |
| Age (years)            | Metropolitan City  | 1727      | 632     | 0.1461    |
|                        | Province           | 1575      | 633     |           |
| Medical benefits       | Non-recipient      | 3057      | 1187    | 0.1391    |
|                        | Recipient          | 245       | 78      |           |
| Type of medical institution | Tertiary hospital  | 1135      | 467     | < 0.0001**|
|                        | Community hospital | 846       | 440     |           |
|                        | Clinic             | 1321      | 358     |           |
| Antipsychotic drugs    | Monotherapy        | 1585      | 448     | < 0.0001**|
|                        | Combination therapy| 1442      | 602     |           |
|                        | Other drugs        | 275       | 215     |           |
| Medication adherence   | 0–50%              | 1176      | 660     | < 0.0001**|
|                        | 50–80%             | 452       | 122     |           |
|                        | More than 80%      | 1674      | 483     |           |
| Treatment after initial diagnosis | Outpatient treatment | 2352      | 759     | < 0.0001**|
|                        | Inpatient treatment| 950       | 506     |           |

* P < 0.05, ** P < 0.001

Table 2 The rate of relapse (per 1000 person-years) by patient characteristics

| Categories          | N (%)       | Relapse | Person-year | Relapse rate (per 1000 person-years) | 95% confidence interval |
|---------------------|-------------|---------|-------------|---------------------------------------|--------------------------|
| Male                | 2289 (50.1) | 635     | 2248.1      | 282.5                                 | 261.1–305.1              |
| Female              | 2278 (49.9) | 630     | 2227.0      | 282.9                                 | 261.4–305.6              |
| Age                 | 4567 (100.0)| 1265    | 4475.1      | 282.7                                 | 261.3–305.5              |
| Metropolitan city   | 2359 (51.7) | 632     | 2332.9      | 270.9                                 | 250.4–292.7              |
| Province            | 2208 (48.3) | 633     | 2142.2      | 295.5                                 | 273.1–319.2              |
| Non-recipient       | 4244 (92.9) | 1187    | 4163.2      | 285.1                                 | 269.2–301.7              |
| Recipient           | 323 (7.1)   | 78      | 311.9       | 250.1                                 | 199.0–310.4              |
| Tertiary hospital   | 1602 (35.1) | 467     | 1643.8      | 284.1                                 | 250.3–323.6              |
| Community hospital  | 1286 (28.2) | 440     | 1173.1      | 375.1                                 | 341.2–411.4              |
| Clinic              | 1679 (36.8) | 358     | 1658.2      | 215.9                                 | 194.4–239.1              |
| Monotherapy         | 2033 (44.5) | 448     | 2047.5      | 218.8                                 | 199.2–239.8              |
| Combination therapy | 2044 (44.8) | 602     | 1928.8      | 312.1                                 | 287.9–337.8              |
| Other drugs         | 490 (10.7)  | 215     | 498.8       | 431.0                                 | 376.2–491.6              |
| 0–50%               | 1836 (40.2) | 660     | 1938.3      | 340.5                                 | 315.3–367.2              |
| 50–80%              | 574 (12.6)  | 122     | 583.0       | 209.3                                 | 174.5–249.0              |
| More than 80%       | 2157 (47.2) | 483     | 1953.8      | 247.2                                 | 225.9–270.0              |
| Outpatient treatment| 3111 (68.1) | 759     | 3049.1      | 248.9                                 | 231.7–267.1              |
| Inpatient treatment | 1456 (31.9) | 506     | 1426.0      | 354.8                                 | 324.9–386.8              |
group with 0–50% medication adherence compared with the group with over 80% adherence was 1.38, which was also significantly high.

The results of the patient group who received inpatient treatment after their initial diagnosis were somewhat different from the group who received only outpatient treatment. In the patient group treated in community hospitals and clinics, the relapse HR was 1.22 and 1.39, respectively, both of which were significantly high. No significant difference in the HR between monotherapy and combination therapy (2 or more antipsychotics) was found. The HR of the group with 0–50% medication adherence compared with the group with over 80% adherence was significantly high at 1.96.

**Discussion**

This study was designed to identify factors affecting relapse in patients with first-episode schizophrenia. The total number of subjects included in this study was 4567 with a total follow-up period of 4475.1 person-years. During this observation period, 1265 patients relapsed. As a result, the factors showing a statistically significant effect on relapse were age, type of medical institution, type of medication used, medication adherence, and the severity of symptoms at the time of their initial diagnosis. In general, the HR of relapse tended to vary according to the severity of symptoms.

Looking at age, the risk for relapse appeared low in patients with a delayed age of onset. Although a previous study showed that there was no correlation between the age of onset and the risk of relapse, the present study revealed that a younger age of onset was associated with a worse prognosis [18, 27]. This observation, that the risk for relapse declined significantly with a delayed age of onset, suggests that symptoms are more severe and recurrence is more frequent in patients diagnosed at a young age. Similar results were observed even when the cases were divided by severity into inpatient and outpatient treatment groups. Wood et al. also reported the same outcomes [28]. To prevent relapse in patients with first-episode schizophrenia, early screening systems would therefore be indicated.

In the analysis by type of medical institution, the relapse HR of patients treated in community hospitals compared with those treated in tertiary hospitals was 1.17, a significantly high result. The HR decreased to 0.75 in those treated in clinics. These results may involve a selection error, however, as the type of medical institution attended after the initial episode of schizophrenia depended upon the severity of symptoms. To eliminate this possibility, we examined the data after separating patients into inpatient and outpatient treatment groups. In the outpatient group, the HR of treatment in clinics compared with treatment in tertiary hospitals yielded a

### Table 3 The Hazard Ratio for relapse by characteristics of patients with first-episode schizophrenia

| Characteristics          | Categories | Status | Univariate | Multivariate |
|--------------------------|------------|--------|------------|--------------|
|                          |            | No relapse | Relapse | Hazard ratio | 95% CI | Hazard ratio | 95% CI |
| Gender                   | Male       | 1654   | 635   | 1.00 (0.90–1.12) | 0.95 (0.85–1.06) |
|                          | Female     | 1648   | 630   | 1.00 (reference) | 0.96 (0.95–1.06) |
| Age (years)              | Metropolitan City | 1727 | 632   | 1.00 (reference) | 1.02 (0.95–1.09) |
|                          | Province   | 1575   | 633   | 1.09 (0.98–1.22) | 1.02 (0.92–1.14) |
| Geographic location      | Non-recipient | 3057 | 1187  | 1.00 (reference) | 1.00 (0.85–1.15) |
|                          | Recipient  | 245    | 78    | 0.85 (0.68–1.07) | 0.85 (0.68–1.07) |
| Medical benefits         | Tertiary hospital | 543  | 230   | 1.00 (reference) | 0.90 (0.83–1.00) |
|                          | Community hospital | 846  | 440   | 1.26* (1.10–1.43) | 1.17* (1.02–1.33) |
|                          | Clinic     | 1321   | 358   | 0.73* (0.63–0.83) | 0.75* (0.63–0.90) |
| Type of medical institution | Monotherapy | 1585 | 448   | 1.00 (reference) | 0.98 (0.84–1.13) |
|                          | Combination therapy | 1442 | 602   | 1.40* (1.24–1.58) | 1.04 (0.88–1.21) |
|                          | Other drugs | 275   | 215   | 2.29* (1.95–2.70) | 2.09* (1.77–2.46) |
| Antipsychotic drugs      | 0–50%      | 1176   | 660   | 1.60* (1.42–1.80) | 1.59* (1.41–1.80) |
|                          | 50–80%     | 452    | 122   | 0.88 (0.72–1.07) | 0.94 (0.77–1.15) |
|                          | More than 80% | 1674 | 483   | 1.00 (reference) | 1.00 (0.86–1.14) |
| Medication adherence     | Outpatient treatment | 2352 | 759   | 1.00 (reference) | 1.00 (0.86–1.14) |
|                          | Inpatient treatment | 950  | 506   | 1.50* (1.34–1.67) | 1.46* (1.24–1.71) |

| Multivariate hazard ratio was calculated including all variables in the table |
| CI confidence interval |
| * P < 0.05 |
Fig. 2 The Hazard Ratio for relapse by characteristics of patients with first-episode schizophrenia, stratified by severity. HR Hazard Ratio. *Adjusted for type of medical institution, type of medication used, and medication adherence. †Adjusted for age, type of medication used, and medication adherence. ‡Adjusted for age, type of medical institution, and medication adherence. §Adjusted for age, type of medical institution, and type of medication used.
The relapse HR for patients treated with other drugs compared with monotherapy with an antipsychotic was significantly high at 1.81, suggesting that antipsychotic drugs are more effective [35]. To prevent relapse, antipsychotic medications should be administered from the onset of schizophrenia, regardless of the severity of symptoms. Combination therapy with more than one antipsychotic medication is becoming more common in the treatment of schizophrenia, and its efficacy is excellent [36, 37]. There was, however, no difference in the relapse HR between monotherapy and combination therapy in this study. The result was the same after adjusting for the severity of symptoms. Thus, to prevent relapse, antipsychotic medications should be administered from the onset; providers must then decide whether to use monotherapy or combination therapy.

Analyzing relapse HR according to medication adherence, the HR of the low-level adherence group (0–50%) compared with the high-level adherence group (more than 80%) was 1.59, a significantly high result. This result was the same in both the inpatient and outpatient treatment groups. These results coincide with previous studies in that the risk of relapse decreases with a higher medication adherence [38, 39].

There are several limitations in this study. First, the data did not provide information about the actual severity of patient with schizophrenia. Therefore, this study performed subgroup analysis by classifying hospital treatment and outpatient treatment in order to exclude the effect of severity. However, it could not confirm effect of severity. Second, in this study, we used indirect measures of medication adherence. Thus, we were unable to confirm whether the patients complied with the prescribed medication or not. Further research is needed to investigate these limitations.

Despite these limitations, our study has a number of strengths. Using the HIRA data, this study confirmed the risk factor for relapse in all patients with first episode schizophrenia in Korea. The results of this study showed that necessity for change of structural, institutional factors as well as medical treatments in managing patients.

**Conclusions**

This study investigated the risk factors for relapse in patients with first-episode schizophrenia using data from the HIRA in order to best represent the Korean patient population. Approximately 28% of the 4567 patients included in this study relapsed over 4475.1 person-years. After adjusting for demographic features, the factors which increased the risk of relapse include a younger age of onset, treatment in clinics and community hospitals, use of medications other than antipsychotic drugs, reduced medication adherence, and high severity of symptoms at the initial diagnosis. The results varied, however, when we stratified by the severity of symptoms. Consequently, the results of this study suggest the need for changes in the structure of care, institutional factors, and medical treatments used to manage patients with first-episode schizophrenia in Korea. It is our hope that this study can be utilized as source material for directing...
therapeutic interventions and improving mental health policies in the future.

Authors' contributions
The authors' responsibilities were as follows: SU formulated the study hypothesis together with CJK, SWR, IHO and SKC performed the statistical analyses and contributed to the first and final draft of the manuscript. SU, MAS, SP, HYL and SKC contributed to the interpretation of the study results. All authors read and approved the final manuscript.

Author details
1 Department of Mental Health Research, National Center for Mental Health, Seoul, South Korea. 2 Department of Psychiatry, Hanyang University College of Medicine, Seoul, South Korea. 3 Department of Preventive Medicine, School of Medicine, Kyung Hee University, Seoul, South Korea.

Acknowledgements
This study was supported by the Korean Mental Health Technology R&D Project funded by the Ministry of Health & Welfare (HM14C2166), Republic of Korea.

Competing interests
The authors declares that they have no competing interests.

Availability of data and materials
According to HIRA data protection regulation, administrative data is made available for specific research projects. Thus, we cannot share the data we used for this study with other researchers.

Ethics approval and consent to participate
This study was approved by the IRB of the National Center for Mental Health (116271-2016-28). We utilized encoded data, making it impossible to identify any patient's personal information.

Funding
This study was supported by a grant of the Korean Mental Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HM14C2166).

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 24 October 2017 Accepted: 15 February 2018 Published online: 02 March 2018

References
1. McGrath J, Saha S, Chan D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67–76.
2. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to olanzapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155(6):751–60.
3. Birchwood M, Macmillan F. Early intervention in schizophrenia. Aust NZ J Psychiatry. 1993;27(3):374–8.
4. Birchwood M, Farquhar A. The critical period for early intervention in schizophrenia. Am J Psychiatry. 1999;155(6):751–60.

Acknowledgements
This study was supported by the Korean Mental Health Technology R&D Project funded by the Ministry of Health & Welfare (HM14C2166), Republic of Korea.
30. Lee JH, Ko BS, Leem JH, Lee SI. Standard model and quality appraisal framework for the organization of primary care. J Korean Med Assoc. 2013;56(10):866–80.
31. Kang SH, Kim BI, Jun CH, Choi BK, Lee SH. Healthcare optimization: current status and vitalization suggestions. J Korean Inst Ind Eng. 2013;39(4):313–24.
32. Lee YM. Health policy for the people. J Korean Med Assoc. 2017;4:286–8.
33. Roh OH, Lee CH, Park A, et al. A study on characteristics of medical expenses and the hospitalization period of hospitalized patients using diem payment system at convalescent hospitals. J Korea Acad Industr Coop Soc. 2016;17:8–10.
34. Park SC, Lee MS, Kang SG, Lee SH. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample. J Korean Med Sci. 2014;29(5):719–28.
35. Álvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull. 2011;37(3):619–30.
36. Pickar D, Vinik J, Bartko JJ. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS ONE. 2008;3(9):e3150.
37. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443–57.
38. Novak-Grubic V. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry. 2002;17(3):148–54.
39. Üçok A, Polat A, Çakır S, Genç A. One year outcome in first episode schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2006;256(1):37–43.